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Abstract
Background: Understanding the aetiologies of neurodegenerative diseases such as Alzheimer’s disease (AD), Pick’s disease
(PiD), Progressive Supranuclear Palsy (PSP) and Frontotemporal dementia (FTD) is often hampered by the considerable
clinical and molecular overlap between these diseases and normal ageing. The development of high throughput genomic
technologies such as microarrays provide a new molecular tool to gain insight in the complexity and relationships between
diseases, as they provide data on the simultaneous activity of multiple genes, gene networks and cellular pathways.
Methodology/Principal Findings: We have constructed genome wide expression profiles from snap frozen post-mortem
tissue from the medial temporal lobe of patients with four neurodegenerative disorders (5 AD, 5 PSP, 5 PiD and 5 FTD
patients) and 5 control subjects. All patients were matched for age, gender, ApoE-e and MAPT (tau) haplotype. From all
groups a total of 790 probes were shown to be differently expressed when compared to control individuals. The results
from these experiments were then used to investigate the correlations between clinical, pathological and molecular
findings. From the 790 identified probes we extracted a gene set of 166 probes whose expression could discriminate
between these disorders and normal ageing.
Conclusions/Significance: From genome wide expression profiles we extracted a gene set of 166 probes whose expression
could discriminate between neurological disorders and normal ageing. This gene set can be further developed into an
accurate microarray-based classification test. Furthermore, from this dataset we extracted a disease specific set of genes and
identified two aging related transcription factors (FOXO1A and FOXO3A) as possible drug targets related to
neurodegenerative disease.
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Introduction
Neurodegenerative diseases are characterised by regional
cellular changes associated with progressive loss (of function) of
neurons that on careful examination of brain pathology is
generally distinctive between diseases. On a clinical level however,
large differences exist and in addition symptoms can vary widely
during the course of the disease. Although classification of patients
is possible into broadly defined clinical and pathological groups,
defining the borders of such classifications is often hampered by
individual variation between patients, even within families with
Mendelian forms of disease [e.g. as is the case in Frontotemporal
dementia (FTD), [1–3]]. Furthermore, towards the endpoint of
disease clinical characteristics of the different disorders converge,
making it even more difficult to classify patients with less typical
disease phenotypes [2].
Characteristic for many neurodegenerative diseases is the
occurrence of characteristic aggregation of specific proteins in
brain. Neurodegenerative disorders may be distinguished upon
presence and absence of disease specific protein aggregates e.g. a-
synuclein in Parkinson, and amyloid precursor protein in
Alzheimer’s disease or the microtubule associated protein tau
(MAPT or tau) as observed in for example AD, FTD, PiD, PSP
[4,5]. Although in this last group of diseases, also referred to as
tauopathies, patients are often distinguishable upon pathology,
patients with less typical or mixed pathology are difficult to
classify, demonstrating the need to understand the underlying
processes behind the pathological changes.
The identification of genetic defects for Mendelian forms of
neurodegenerative disorders has given important new clues about
molecular pathways involved in their aetiology, and has
contributed to a better classification systems for a range of these
neurodegenerative disorders [3]. Although Mendelian genes
usually explain only a minority of cases, their identification has
opened up new research directions and this has given us important
new clues about the molecular pathways involved. As the
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Mendelian forms of disease do not always result in uniform clinical
and pathological findings, it can be hypothesised that genetic and/
or environmental modifying factors contribute to the disease
process. Evidence is emerging that some of the identified genes (i.e.
MAPT, a-Synuclein) also play a role in the more common (non-
Mendelian) forms of the disease and it is generally accepted that
the aetiology of the non-Mendelian forms of neurodegenerative
disorders must be explained by a combination of genetic and
environmental factors and that the effects of the sum and
interactions of these factors must be reflected in gene expression
patterns on both the RNA and protein level.
Identification of the complete network of genetic and environmental
factors involved in a disease is a daunting task. In the past, genetic
association studies of candidate genes tried to identify risk factors once
at a time. The full elucidation of the genetic influences of
neurodegenerative diseases, however, requires a thorough understand-
ing of the relationship between the variation present in our genome
and the corresponding phenotypes. The ability to collect this genomic
information, including sequence and genotype information, gene/
protein expression levels and cell biological parameters, rapidly and
inexpensively, has long been a bottleneck to realizing this goal.
However, in the past 15 years genomic approaches have entered the
functional evaluation phase and newly developed high-throughput
methods now provide enormous amounts of raw data for that purpose
(see e.g. [6,7]. The ability to perform these highly parallel genomic
assays depends on two fundamental characteristics of the assays: a
highly parallel array based read-out and an intrinsically scalable
multiplexing sample preparation. Gene-expression profiling was the
first type of genomic assay to be parallelized and over the years using
high-density DNA arrays for readout from a single-tube sample
preparation has matured into a ‘‘standard’’ molecular biology tool for
many research institutions. Gene expression profiling has been used for
neurodegenerative disorders but mainly with the aim to identify
molecular pathways affected by the disease process [8,9]. An important
criticism on these studies has been that human post-mortem brain
represents an end stage of disease where a total collapse of the system
might lead to many changes not relevant for the disease process, which
is reflected in the observance of converging clinical symptoms. An
alternative approach would therefore be to use animal models such as
transgenic mice with human mutations. However, this approach only
partly overcomes the problem. There is indeed an advantage that one
can study the expression patterns longitudinally, however, most animal
models mimic only part of the human phenotype and therefore the
relevance of findings is difficult to establish
Studying end stage human brain material, although not ideal, can
still provide important information and by using a different study
design than commonly used (i.e. comparing a group of patients with
a specific disease with a control group) the value of human material
can be improved. We have therefore systematically compared four
groups of patients of different disorders, with significant overlap in
clinical and pathological characteristics with controls and searched
for discriminating gene expression patterns as well as common
denominators for more than a single disease. Furthermore, we
compared our original group with a group of independent samples
to confirm our obtained results were robust and reliable. This study
is a first attempt to distinguish different neurodegenerative disorders
with tau pathology (and related disease processes) based upon
genome wide gene expression patterns.
Results
Clustering
We performed a hierarchical cluster analysis based on
similarities in gene expression without pre-grouping of samples
based upon clinical, pathological or genetic characteristics. No
clustering was observed for age of death, gender, ApoE-e and
MAPT haplotype or post mortem delays (see more details about
brain samples in Table 1).
Considerable overlap in expression patterns for samples with
distinct clinical and pathological findings was detected even
though most Frontotemporal lobe degeneration [26] samples (i.e.
FTD and PiD samples) clustered separately from the other samples
(results not shown). A straightforward distinction based on existing
clinical and pathological criteria between all tested neurodegen-
erative diseases is therefore not immediately obvious from these
gene expression data. Possible explanations for this ambiguous
clustering may be variation in lifetime environmental influences
(e.g. life style or the conditions under which the patients had died)
and genomic-background effects for individual patients, which
would contribute to population expression variation (i.e. noise).
Whereas an alternative explanation would be that the neurode-
generative disorders fail to influence the expression of the majority
of genes between sample groups. In order however to restrain the
influence of normal variation we used the gene expression data
from the control group as reference. Using significance analysis of
microarrays (SAM) [22] we then compared each clinically and
pathologically defined patient group to the control group and
identified those genes that were expressed significantly different
from control levels (see Table S1). Microarray results for
significantly changed genes were confirmed by quantitative reverse
transcriptase PCR (qRT-PCR) (Figure 1B). Interestingly the
expression levels of several neurodegeneration related genes (i.e.
MAPT, GRN, APP or PSEN1 and PSEN2) showed differences
from the background levels in all clinical and pathological related
groups, but failed to reach significance due to large individual
variability (results not shown).
This analysis defined a new data set consisting of 790
significantly altered probes (,730 genes; Table S2) between
patients and controls. Re-clustering using this reduced gene set
resulted in separation of samples into clinically and pathology-
related groups (see Figure 1A). All controls and 4 of the 5 PSP
patients formed separate clusters. The FTD and PiD disease
samples clustered as a single large group and four of five
Alzheimer samples also clustered together. However, an Alzhei-
mer sample (AD5) grouped with the PSP group (see Figure 1A).
Interestingly, we observed (Table S1 and Figure 1C) that the AD
samples and control samples were highly similar (only 11
differently expressed genes) in gene expression. Although this
seems unexpected, it might be explained by an observation made
by drs. K. Bossers and J. Verhaagen (pers. comm.) that high
variability of gene expression between different samples was seen
in earlier and later Braak stages, whereas in intermediate Braak
stages (stage III and IV) expression was more similar. Because
expression levels were more variable between our patients, it
becomes more difficult for the permutation analysis to pick up
significant gene expression changes.
We further observed (Figure 1C) that the majority of genes in
the reduced data set of 790 probes that were significantly
differently expressed from the control group, were specific for
single patient groups. To identify common denominators for the
different diseases we reanalysed the dataset by including only those
genes that were significantly altered in at least two patient groups.
This reduced the gene set to only 166 probes (Table S3).
Interestingly we observed no common gene significantly altered in
all patient groups.
Using this more stringent gene set, clustering further improved
the separation of samples in clinically and pathologically defined
groups, especially for the AD, PSP and control samples (see
mRNA Classifies Tauopathies
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Figure 2A). Surprisingly FTD and PiD disease samples still clustered
as a single large group. Although the considerable overlap in gene
expression might be explained by the overlap in clinical symptoms
and affected brain regions, the group of FTD patients do not show
extensive tau pathology as they were classified as Constantinidis
type C1 while the PiD patients all showed extensive tau pathology
(Constantinidis type A) suggesting that the observed tau pathology is
not necessarily indicative for the molecular pathways affected. We
noted that the FTD and PiD samples only showed overlap for a
small subset of genes significantly different from control group
levels, whereas for the majority of genes in the dataset expression
seemed unrelated (see Figure 1C). Since clustering of the two sample
groups was very robust, this suggested a strong correlation in gene
expression between the two sample groups. Therefore we
constructed correlation plots between the 166 probes and the 790
probes of the larger dataset, and calculated correlation coefficients.
The correlation coefficient between both illnesses was approxi-
mately 1 (data not shown) confirming that PiD disease and FTD are
closely related disorders based on clinical, pathological and mRNA
gene expression findings.
Figure 1. Initial analysis and confirmation of the microarray data. Figure 1A. Clustering of all 25 samples using the background filtered
dataset of 790 probes. Figure 1B. Results of quantitative PCR experiments for 3 genes (FOXC1, SASH1 and MOXD1) that were significantly differently
expressed in Alzheimer’s disease vs. controls. Experiments were done in duplo (a and b) using cDNA from two separate isolations of the same brain
sample (Exp 1 and 2). Statistical testing was done using a Univariate Analysis of Variance with p,0.001 in all samples. Similar results were observed in
the other tested illnesses. Figure 1C. Graphical overview of probes and their correlation between pathology defined groups. Amount of up- and
down-regulated probes is shown with up- or downwards facing arrowheads. Pathology defined groups are represented as coloured ellipses;
Alzheimer’s disease (AD): blue, Pick’s disease (PiD): red, Frontotemporal dementia (FTD), yellow and Progressive Supranuclear Palsy (PSP): green.
doi:10.1371/journal.pone.0006826.g001
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Although the majority of samples clustered within their
clinically and pathologically related sample group, two samples
(AD5 and PSP1) did not (see Figure 2A). Since, gender, age at
death, ApoE-e and MAPT haplotype could not explain why gene
expression in these samples was distinct from related samples, we
evaluated the medical history of these samples in more detail.
Sample PSP1 showed a somewhat longer post mortem delay
than the average of our samples (8.55 hours; average for samples
5:15 hours); however RNA quality, noise levels and the number of
detected probes on the microarrays did not differ form other
samples (see Table S4[A and B]). Although this sample was
pathologically classified as PSP, the patient originally was clinically
diagnosed with corticobasal degeneration, which shows consider-
able phenotypic overlap with PSP [27]. Furthermore, this patient
had died following euthanasia (Nesdonal 10 mg i.v., Pavulon
1000 mg i.v.), which indicates a substantial period of unbearable
suffering for the patient prior to this medication and this might
have had an influence on RNA expression patterns. We therefore
excluded this sample from further analysis.
Sample AD5 was from an Alzheimer’s disease patient who was
reported to suffer from epileptic seizures and motoric disturbances.
These additional clinical findings might explain why this case did
not group with the other AD cases. Because of these atypical
findings this patient was excluded from further analysis.
In conclusion, using a stringent gene set consisting of 166 probes
it was possible to discriminate controls, AD and PSP cases from
each other and clearly discriminates these groups from the group
of FTD/PiD disease samples, i.e. a FTLD [26] group.
We then tested whether this dataset would also be valid in an
independent group of patients. We acquired brain material from 6
additional cases: two AD (Braak stage 6), two PSP and two Pick/
FTD samples [i.e. one sample with classical PiD disease
(Constantinidis type A), and one with FTD (Constantinidis type
C1)]. All samples matched the ones from the earlier experiment.
RNA was isolated, labelled and run on new Affymetrix GeneChip
Human Genome U133 Plus 2.0 microarrays by the LGTC
according to protocol. All microarray data was normalised using
GeneChip Operating Software (GCOS) 3.0 (Affymetrix, Inc.,
Santa Clara, California, USA).
Considering the results of our first experiment we first
performed cluster analysis using the set of 790 significantly
different expressed probes. To correct for inter-experimental
error, all 790 probes were standardised between the two
experiments by dividing the 790 genes from the original dataset
and the new dataset by the average expression ratio per probe in
Microsoft excel (Microsoft Corporation, Redmond WA, USA).
Since the second set of samples did not include controls,
standardisation was only done using patient samples from the
first dataset. This correction is necessary since the ratio of gene
expression per probe from the first 20 experiments and the latter
6 experiments was on average 1.5 times higher (data not shown).
Next, expression of independent genes (Expn) was transformed
to fit between 1 and 0 using the minimal (Expmin) and maxi-
mal expression (Expmax) according to following formula: (Expn
2Expmin/(Expmax2Expmin)), and hierarchical cluster analysis
was done using Cluster3.
Since expression data for the 166 overlapping probes gave best
results to discriminate the different neurodegenerative disorders
(Figure 2A) however, we extracted from this larger dataset the
corrected expression data for the 166 probes determined
previously. Examining only the new PSP and FTD/PiD disease
samples in the cluster analysis with this 166 probes containing
dataset, confirmed that this probe-set could discriminate PSP,
FTD/PiD disease from controls based on gene expression (see
Figure 2B). However when new Alzheimer’s disease samples were
also included, they did not cluster together with matching samples
from the previous experiment, see Figure 2C. As mentioned
above, this was hardly surprising since we observed very few
differences between the AD and control samples in our first
experiment, which might be explained by the observation (see e.g.
Figure 1A) that AD patients with Braak stage 6 have heteroge-
neous gene expression, which we suggest might be caused by the
severe neurodegeneration present in this region.
In conclusion, the current identified set of 166 genes is suitable
to distinguish PSP samples from controls and FTD/PiD disease
samples upon expression, furthermore, our results show that
FTD/PiD disease samples behave as one group that can be
distinguished from PSP samples and non demented controls.
Figure 2. Analysis of original and new samples using the refined microarray data set. Figure 2A. Clustering of all 25 samples using the
refined dataset of 166 probes. Figure 2A. Clustering of selected 23 samples and new PSP, FTD and PiD disease samples. Figure 2C. Clustering of
selected 23 samples and new PSP, FTD and PiD - and Alzheimer’s disease samples. Sample names are as in Figure 1.
doi:10.1371/journal.pone.0006826.g002
mRNA Classifies Tauopathies
PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6826
Pathway analysis
Since our gene expression data could distinguish patient samples
from non-demented controls and from each other into pathology
related groups we explored whether our data would also be
suitable for identifying disease-related molecular pathways.
We used the ‘‘Ingenuity Pathways Analysis’’ on a subscription,
web-delivered application that enables biologists to discover,
visualize, and explore networks relevant to their experimental
results such as gene expression array datasets. The Ingenuity
database contains literature based manually curated gene ontology
data, which decreases the hypothetical character of detected
interactions and the validity of the interactions can be re-assessed
from literature. In addition, the Ingenuity Pathway Analysis
software grants the possibility to determine likelihood of observed
changes using statistical analysis (see materials and methods for
details). To increase reliability of the identified interactions even
more we also limited ourselves to known canonical pathways.
Since our results showed that especially the PSP samples could
be robustly distinguished from the other diseases, we focussed our
analysis on PSP and investigated how disease related alternatively
expressed genes in this disease group influence canonical
pathways. To determine pathways that were significantly linked
to the illness we created two separate datasets with genes that were
statistically different between PSP cases and controls. We chose to
calculate two separate datasets using SAM (one not stringent, and
one stringent) to circumvent the issues that a stringently
ascertained dataset might miss relevant pathways (because too
few genes are entered in the analysis) or that a larger, less
stringently selected set of genes would contain too many false
positives. We chose to define only those pathways as interesting
when detected in both analyses.
The low stringency set was defined by setting the significance
threshold such that we accept ,40 median false positives in the
SAM analysis. Since our data contained approximately 40.000
probes this approach corresponds to using a nominal p-value of
0,001. The resulting gene set contained approximately 1600
probes with a false discovery rate (FDR) of 0.025. On the other
hand, for the high stringency set we accepted only 1 median false
positive. The resulting gene set contained 266 probes at an FDR of
0.004.
To determine the likelihood for a pathway to be affected we
used the statistics of the Ingenuity Pathway Analysis. This analysis
compares the number of user-specified genes that participate in a
pathway, relative to the total number these genes in all pathway
annotations stored in the Ingenuity Pathways Knowledge Base,
and gives significance values using the right-tailed Fisher’s Exact
Test, to indicate which pathways seem affected by the disease
process. Using the less stringent dataset, five pathways were
detected to be affected, among which the insulin receptor
signalling (p = 0.047) (see Figure 3A). A further two pathways
showed a trend toward significance (i.e. IGF-1 [p= 0.051] and
PTEN [p= 0.055]; see Figure 3A).
Next, to confirm these results and to determine relevant target
genes in these pathways, we repeated the analysis with a stringency
of 1 median false positive per dataset (implicating essentially all
detected genes to be disease related) to increase confidence that
pathways were disease related. With this dataset we obtained again
five affected pathways. Three of earlier mentioned pathways were
detected to be significantly affected (i.e. insulin receptor signalling
[p= 0.025]; IGF-1 [p= 0.006] and PTEN [p= 0.039]; see
Figure 3B), and in addition the EGF and Estrogen receptor
signalling pathways. The observation that several of the initially
detected pathways did not remain significant in our more stringent
analysis suggests that they could be false positive findings because
of inclusion of house keeping processes in the initial dataset and
over-detection of small and less defined pathways in the more
stringent dataset. All three pathways show considerable overlap in
gene content. Interestingly, the insulin/IGF-1 signalling (IIS)
pathway has an important role in the ageing process [28,29] and
the transcription factors FOXO1A and FOXO3A, previously
implicated as key regulators of the ageing process [29–33], were
significantly up-regulated in our PSP data set.
To determine whether the upregulation of FOXO1A and
FOXO3A was specific for PSP, we tested whether these genes
were also differentially expressed in the other disease groups. In
FTD samples both FOXO1A and FOXO3A were indeed also
significantly upregulated, whereas in PiD only FOXO3A was
significantly upregulated. In Alzheimer’s disease samples no
FOXO factor upregulation was observed, however as mentioned
the AD samples and controls vary only on 11 genes, and the power
to detect biologically relevant changes might be limited. This
however might mean that FOXO3A might be a common
neurodegeneration factor, whereas FOXO1A might be associated
with both PSP and FTD.
Discussion
Our results demonstrate that it possible to separate patients with
pathologically confirmed PSP, AD and FTD/PiD from each other
based on their gene expression patterns. In addition, we identified
a gene set of 166 genes that might be developed into a tool to aid
in post-mortem classification of patients. Although we identified
genes that were differently expressed in more than one patient
group we did not find differentially expressed genes common to all
patient groups, demonstrating that although there is considerable
overlap between these disorders different molecular pathways are
affected. However, our analysis might have been overly stringent.
We used this high stringency to minimize false positive findings.
We did not reanalyse the data using lower stringency but instead
aim in future experiments to extend the current study to additional
brain regions and samples.
Analysis of human post-mortem brain material might be
complicated by expression changes because of events just prior
to death. To control for such artefacts, we compared gene
expression patterns with those from control brains. Interestingly
we found considerable overlap in gene expression between our
Braak stage 6 AD cases and controls. We hypothesise these
findings might be explained by the severity of neurodegeneration
in this region and should be confirmed by including AD samples
with different Braak stages or less affected brain regions.
Our results on samples with frontal forms of dementia (i.e. FTD
and PiD) show that these cases not only have considerable overlap
in clinical symptoms and affected brain regions but also in gene
expression (see Figure 2A and B) confirming the validity to group
them under the general term Frontotemporal lobar degeneration
(FTLD) [26]. However to rule out that processes correlated with
severity of neurodegeneration are the reason of the similarity in
gene expression observed in FTD and PiD disease, our results
should be validated in other brain regions. Similarly, including
differently affected regions may provide more details why some
regions are more sensitive to neurodegeneration and which
processes are involved.
The observation that the insulin/IGF-1 signalling pathway is
affected (although not equally) in PSP, FTD and PiD makes this
pathway an interesting target for further research. The function of
FOXO transcription factors is diverse and depends on activity of
other transcription factors and cell type. FOXO transcription
factors influence a diverse group of cellular mechanisms, including
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glucose metabolism [34], cell cycle [35–39], cell differentiation
[40,41], regulation of apoptosis [42–45] or decrease of reactive
oxygen species (ROS) [36,38,39]. Therefore depending on signal
and cell type they balance stress resistance, growth and cell death.
For these reasons FOXO transcription factors can be best defined
as regulators of cell fate [46].
Their mode of action however largely depends on interactions
with upstream pathways, since these regulate FOXO phosphor-
ylation, acetylation or ubiquitinilation [47], which influences
FOXO stability and interaction with downstream promoters.
Therefore characterisation of the upstream pathway influences cell
outcome. In our microarray experiments an up regulation of
IGF1-R and RAF1 was observed. Synergy between PI3K/Akt and
RAF/MEK/ERK pathways has been described to prevent
apoptosis and is therefore protective [48].
FOXO proteins have been reported to decrease ROS by
increasing the radical scavenging proteins Mn superoxide
dismutase (MnSOD) and catalase [36,38,39]. In several neurode-
generative disorders oxidative stress has been suggested to be
correlated with disease aetiology, and therefore may provide a
possible explanation. Recently in C. elegans a link between
aggregation-mediated toxicity and decreased insulin/IGF-1-like
signalling was shown. Downstream transcription factors (heat
shock factor-1 and Daf-16) regulated (dis-)aggregation activities to
promote cellular survival in response to constitutive toxic protein
aggregation [49]. Therefore, this pathway might provide a
Figure 3. Significantly changed canonical pathways in PSP brain. Figure 3A. Significantly changed canonical pathways in PSP brain in the
uncorrected dataset. Threshold for significance is shown in the dotted line. * signifies the significantly deregulated (p = 0.047) Insulin Receptor
Signalling pathway andˆ signifies the almost significantly deregulated (p = 0.051 and p=0.055) IGF-1 and PTEN Signalling pathways respectively.
Figure 3B. Significantly changed canonical pathways in PSP brain in the corrected dataset. Threshold for significance is shown in the dotted line. **
signifies the significantly deregulated (p = 0.025) Insulin Receptor Signalling pathway for both analysis and * signifies the significantly deregulated
(p = 0.006 and p= 0.039) IGF-1 and PTEN Signalling pathways, respectively.
doi:10.1371/journal.pone.0006826.g003
mRNA Classifies Tauopathies
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6826
mechanistic link to aggregation-mediated proteotoxicity and
neurodegeneration.
These results imply that instead of focussing on a single gene
only, future experiments to study the involvement of (e.g. these
FOXO) factors in PSP, FTD, PiD and other neurodegenerative
diseases should be focussed on whole pathways and their
interacting pathways, instead of focussing on single genes in order
to obtain a more complete insight into the true involvement of
these factors in neurodegeneration.
Ethics Statement
In agreement with Dutch law, no ethics statement is required.
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conducted according to the ethical declaration of the Netherlands
Brain Bank (see Supplementary File S1).
Materials and Methods
Brain samples
Snap frozen brain material from 4 pathologically defined
disease groups (i.e. PSP, PiD disease (Constantinidis type A),
FTD (Constantinidis type C1; dementia lacking distinctive
histology)[10], AD (Braak stage 6) [11]) and controls were
obtained from the Netherlands brain bank. To obtain sufficient
statistical power each groups consisted of 5 samples. Because
there are considerable regional differences in pathology between
disease groups we selected to use the medial temporal lobe to
determine gene expression patterns in all patients, as this is an
affected region for all patients. All brain samples were matched
by age (all groups p.0.05, t-test), post mortem delay (all groups
p.0.05, t-test), gender (in total 13 males and 12 females and
every group consisted of 2 or 3 males), MAPT haplotype
(p.0.05, Fischer exact test) and ApoE-e haplotype (p.0.05,
Fischer exact test). Although all patients were selected to be non-
familiar, all patients were screened for Microtubule Associated
Protein Tau (MAPT) and Progranulin (GRN) mutations and
MAPT haplotyping. DNA was isolated from brain using the
Gentra PUREGENE DNA purification kit (QIAGEN Benelux
B.V., Venlo, The Netherlands) according to protocol with the
exception that all buffer amounts per mg of brain tissue were
doubled due to the high protein and fat content of brain material.
Mutation and genotype analysis was performed as described
before [12–14].
In our confirmation experiment two additional PSP patients,
two Alzheimer’s disease patients (Braak stage 6 [11]), one FTD
patient (Constantinidis type C1) and one PiD disease patient
(Constantinidis type A [10]) were included and matched according
to the same inclusion criteria.
RNA isolation, quality assessment and labelling
Post-mortem delay might influence RNA quality [15–21].
Therefore to obtain RNA of adequate quality we selected patient
samples with a relatively short post-mortem delay (on average
5:15 hours with the largest being 8:55 hours). RNA was isolated
from 100–200 mg snap frozen brain material that had been stored
at 280uC. RNA was isolated in groups of four samples, to prevent
degradation during the isolation procedure, using 2–4 ml RNA-
Bee (Iso-Tex diagnostics Inc, Friendswood, Texas, USA) and
purified using the RNeasy RNA cleanup kit (QIAGEN Benelux
B.V., Venlo, The Netherlands) according to manufacturer’s
protocol. It was then quantified using a spectrophotometer and
quality was assessed using an Agilent 6000 Nano bioanalyser chip
(Agilent Technologies Netherlands B.V., Amstelveen, The Nether-
lands). RNA samples were only included when the ratio between
28 s and 18 s rRNA was higher than 0.5 and contributed to more
than 15% of total mRNA. An average sample, as determined by
results from the Agilent 6000 Nano bioanalyser chip, was labelled
and run on an Affymetrix GeneChipH Test3 Array (Affymetrix,
Inc., Santa Clara, California, USA) to determine RNA quality and
labelling. Ten mg of total RNA was transcribed into cDNA and
subsequently into biotin labelled complement RNA (cRNA) using
the Affymetrix one cycle target labelling kit (Affymetrix, Inc.,
Santa Clara, California, USA). All samples were hybridised by the
Leiden Genome Technology Center (LGTC, Leiden, The
Netherlands) on Affymetrix GeneChip Human Genome U133
Plus 2.0 microarrays according to protocol. Quality control
showed that the amount of detected probes was on average
between 40 and 50 percent (see Table S4A); furthermore
detectable noise levels were low (see Table S4B) and thus RNA
degradation was low. Therefore all our samples were of sufficient
quality to proceed.
Microarray analysis, clustering and pathway analysis
All microarray data have been deposited in ArrayExpress, the public
archive for transcriptomics and related data at the EBI (http://www.
ebi.ac.uk/microarray-as/ae/; accession number: E-MEXP-2280), and
can be accessed through the following direct link: http://www.ebi.ac.
uk/microarray-as/ae/browse.html?keywords=E-MEXP-2280. All
microarray data was normalised using GeneChip Operating Software
(GCOS) 3.0 (Affymetrix, Inc., Santa Clara, California, USA). Only
marginal (0.06,p,0.04) and present (p,0.04) probe sets were used
for subsequent analyses. Data analysis was done using the statistical
package Significance Analysis of Microarrays (SAM) [22] in R (http://
www.r-project.org) since previous results had shown this test to give
valid results [23,24]. Permutation analysis on a test set showed a
minimum of 300 permutations needed to be performed for consistent
results. The low stringency set was defined by setting the significance
threshold such that we accept ,40 median false positives in the SAM
analysis. Since our data contained approximately 40.000 probes this
approach corresponds to using a nominal p-value of 0,001. The
stringent dataset was obtained by increasing the significance threshold
to obtain less than 1 median false positive per group.
To correct for inter-experimental error between original and
control datasets, all 790 probes obtained in the stringent analysis
were standardised between the two experiments by dividing
expression values of the 790 genes from the original dataset and
the new dataset by the average expression ratio of the two datasets
per probe in Microsoft excel (Microsoft Corporation, Redmond
WA, USA). Since the second set of samples did not include
controls, standardisation was only done using patient samples from
the first dataset. Next, expression of independent genes (Expn) was
transformed to fit between 1 and 0 using the minimal (Expmin) and
maximal expression (Expmax) according to following formula:
(Expn2Expmin/(Expmax2Expmin)), and hierarchical cluster analy-
sis was done using Cluster3 [25].
Significance of analysed pathways was calculated in Ingenuity
(www.ingenuity.com) using the ‘‘Functional Analysis’’ option. The
significance value associated with this Analysis for a dataset is a
measure for the likelihood genes from the dataset file under
investigation participate in that function. The significance is
expressed as a p-value, which is calculated using a right-tailed
Fisher’s Exact Test. The p-value is calculated by comparing the
number of user-specified genes of interest that participate in a
given function or pathway, relative to the total number of
occurrences of these genes in all functional/pathway annotations
stored in the Ingenuity Pathways Knowledge Base (83 in IPA
version 3.5; [explanation adapted from official text IPA website]).
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Quantitative PCR and Primers
To confirm microarray results, cDNA was made according to
standard protocols at 50uC using superscript III, (Invitrogen,
Breda, The Netherlands). To confirm microarray data, primers for
MOXD1; ZNF589; FOXC1; SASH1; ACAD2; SEPT2;
PNPLA2; TNPO1; CBL; GOLPH4; NRD1; PARD3; PTEN;
NPIP; BTBD14A; CENTB5; HPRT and b-ACTIN were
designed for quantitative PCR using Primer Express 2.0.0 software
(Applied Biosystems, Foster City, California, USA). All qPCRs
were standardized to b-Actin and HPRT signals that were run in
parallel (for all primer sequences see Table S5). PCRs were
performed on an Applied Biosystems 7900HT Fast Real-Time
PCR System (Applied Biosystems, USA) using standard settings.
Supporting Information
Table S1 Overview of genes detected to be significantly different
from background levels determined using non-demented controls.
Amounts of significant different probes are given per pathology-
defined group. Alzheimer’s disease: AD, Pick’s disease: PiD,
Frontotemporal dementia: FTD and progressive supranuclear
palsy: PSP. When possible probes are named using official gene
symbol names. Gene symbol: official genbank gene symbol. Gene
Title: official genbank gene name. ---: Unknown
Found at: doi:10.1371/journal.pone.0006826.s001 (1.12 MB
DOC)
Table S2 Compiled table of all 790 probes detected to be
significantly different from background and overlapping in at least
two different pathologically defined groups. When possible probes
are given in official gene symbol names. Gene symbol: official
genbank gene symbol. Gene Title: official genbank gene name. ---:
Unknown
Found at: doi:10.1371/journal.pone.0006826.s002 (0.83 MB
DOC)
Table S3 Compiled table of all 166 probes detected to be
significantly different from background and overlapping in at least
two different pathologically defined groups. When possible probes
are given in official gene symbol. Gene Title: official genbank gene
name. ---: Unknown
Found at: doi:10.1371/journal.pone.0006826.s003 (0.20 MB
DOC)
Table S4 Overview of detected probes, signal strengths,
background and noise levels.
Found at: doi:10.1371/journal.pone.0006826.s004 (0.17 MB
DOC)
Table S5 Primer sequences of primers used for quantitative
reverse transcriptase confirmation of the microarray data.
Found at: doi:10.1371/journal.pone.0006826.s005 (0.04 MB
DOC)
Supplementary File S1 Ethical Declaration of The Nether-
lands Brain Bank
Found at: doi:10.1371/journal.pone.0006826.s006 (0.09 MB
PDF)
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